TB-500 (Thymosin Beta-4): Dosage, Benefits & Side Effects

By Peptide Assistant Editorial Team · · · 26 sources cited

Overview

TB-500 is a synthetic version of the active region (amino acids 17-23) of Thymosin Beta-4, a 43-amino acid protein naturally produced in high concentrations by platelets, wound fluid, and most tissues in the body. It is one of the most widely used healing and recovery peptides, used on the strength of research on full-length Thymosin Beta-4, which promoted tissue repair, reduced inflammation, and accelerated wound healing in animal studies of skin, cornea, and heart. The TB-500 fragment itself has been studied far less: a few cell and animal experiments, and no human trials. TB-500 has gained enormous popularity in both the athletic and clinical research communities for its versatile regenerative properties.

Mechanism of Action

TB-500 contains the key actin-binding domain of Thymosin Beta-4 (Tβ4), centered on the sequence LKKTETQ. Its primary molecular function is to sequester monomeric G-actin, preventing its polymerization into F-actin filaments. This may seem counterintuitive for a healing peptide, but the regulation of actin dynamics is fundamental to cell migration — the process by which repair cells (keratinocytes, endothelial cells, fibroblasts, stem cells) move to injury sites. By maintaining a pool of available G-actin and promoting actin filament reorganization, TB-500 dramatically enhances cell motility. In wound healing, TB-500 promotes the migration of endothelial cells and keratinocytes to the wound site, accelerating re-epithelialization and angiogenesis (new blood vessel formation). Full-length Tβ4 induces the expression of VEGF (vascular endothelial growth factor) in cell studies, promoting the formation of new capillary networks that supply regenerating tissue with oxygen and nutrients. Full-length Tβ4 has anti-inflammatory properties in cell and animal studies, attributed mainly to its N-terminal Ac-SDKP region, which TB-500 does not contain. Tβ4 lowered IL-1β and several chemokines in injured mouse corneas, blocked NF-κB activation in human corneal cells, and reduced the M1 (pro-inflammatory) macrophage phenotype in a mouse liver disease model. This shifts the immune response from damage-control to active tissue remodeling. In cardiac tissue, full-length Tβ4 (not TB-500) has shown notable effects in mice — it activates epicardial progenitor cells, promotes cardiomyocyte survival after ischemic injury, and reduced fibrosis after ischemia-reperfusion. In hair follicles of rats and mice, Tβ4 stimulates stem cell migration and differentiation, promoting hair growth. TB-500 also upregulates matrix metalloproteinases (MMPs) that remodel the extracellular matrix during tissue repair, and full-length Tβ4 promotes the production of laminin-5, a key component of the basement membrane.

TB-500 (Thymosin Beta-4) Benefits: What the Research Shows

  • Sosne et al. (2002, Experimental Eye Research) demonstrated Tβ4 promoted corneal wound healing and reduced inflammation after alkali injury in mice
  • Bock-Marquette et al. (2004, Nature) showed Tβ4 enhanced early cardiomyocyte survival and improved cardiac function after coronary artery ligation in mice
  • Malinda et al. (1999, Journal of Investigative Dermatology) showed Tβ4 increased re-epithelialization of full-thickness wounds in rats by 42% at 4 days and by up to 61% at 7 days compared with saline
  • Philp et al. (2004, FASEB Journal) demonstrated Tβ4 promoted hair growth in rats and mice by activating follicular stem cells
  • Smart et al. (2007, Nature) showed Tβ4 reactivated epicardial progenitor cells from adult mouse hearts, suggesting cardiac regeneration potential
  • Crockford et al. (2010, Annals of the New York Academy of Sciences) reviewed Tβ4's role in wound healing and tissue repair across multiple organ systems
  • Sosne et al. (2007, Experimental Eye Research) showed Tβ4 suppressed TNF-α-induced NF-κB activation in human corneal epithelial cells; Goldstein et al. (2012) reviewed its anti-inflammatory effects
  • Phase II trials of full-length Tβ4 (not TB-500) have been run for skin and eye conditions: a 73-patient venous ulcer trial suggested faster healing at one dose, and a nine-patient severe dry eye trial reported improved signs and symptoms

TB-500 (Thymosin Beta-4) Dosage

  • Loading phase: 2–2.5 mg subcutaneous injection twice per week for 4–6 weeks
  • Maintenance phase: 2–2.5 mg once per week or biweekly after loading
  • For acute injuries: 5 mg twice per week for 2–3 weeks, then taper to maintenance
  • Subcutaneous injection in the abdominal area; some inject near the injury site though systemic distribution is rapid
  • Can also be administered intramuscularly for localized muscle injuries
  • Typical full cycle: 6–12 weeks (4–6 week loading + 4–6 week maintenance)
  • Some protocols alternate: 2 weeks on, 2 weeks off for extended use
  • Best combined with BPC-157 for synergistic healing — different but complementary mechanisms
  • No food timing restrictions; inject at a consistent time of day
TB-500 dosage calculator: get your dose in syringe units →

Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.

TB-500 (Thymosin Beta-4) Side Effects & Safety

Known Side Effects

  • Side effects of TB-500 have not been studied in humans (the FDA has identified no human exposure data for the fragment); the effects listed below come from user reports
  • Temporary lethargy or fatigue in the first few days of use (often described as the body diverting energy to repair)
  • Head rush or lightheadedness immediately after injection (transient)
  • Mild nausea in some individuals, particularly with higher doses
  • Injection site redness, swelling, or itching
  • Theoretical concern about promoting growth of existing cancers (due to angiogenic and cell-proliferative properties). High Tβ4 levels have been linked to tumor progression and metastasis in laboratory and tissue studies; this has not been studied in people using TB-500
  • Temporary increase in inflammation at injury sites as the healing process activates (sometimes perceived as a flare-up)

Safety Profile

TB-500 has been sold as a veterinary preparation and used in racehorses, where it is controlled as a doping agent, but no human safety data exist for it: the FDA has not identified any human exposure data for the TB-500 fragment. Thymosin Beta-4 is naturally present in all human cells at high concentrations, which provides inherent biocompatibility. Published trials of full-length Tβ4 (intravenous in healthy volunteers, topical for venous ulcers and dry eye) reported no serious safety problems, but those trials did not use the TB-500 fragment. The primary theoretical concern is related to its angiogenic and cell-proliferative properties — patients with active malignancy should avoid TB-500, as promoting new blood vessel formation could theoretically support tumor growth. The research is mixed: high Tβ4 expression has been linked to tumor progression and metastasis in several cancers, while one study found tumor-suppressive effects in multiple myeloma. It is not recommended during pregnancy or lactation due to lack of safety data. No drug interactions are established. TB-500 does not affect hormonal axes (testosterone, GH, thyroid). It is prohibited by WADA at all times (the Prohibited List names "thymosin-β4 and its derivatives e.g. TB-500"), and the FDA lists the TB-500 fragment among bulk drug substances that may present significant safety risks in compounding.

What to Expect

This timeline comes from user reports; TB-500 has not been studied in humans. Week 1–2 (loading): Subtle effects begin. Increased flexibility and reduced stiffness in injured areas. Some users experience temporary fatigue or mild discomfort at old injury sites as the healing process activates. Sleep quality often improves. Week 2–4: Noticeable improvement in injury recovery. Tendon and ligament injuries show reduced pain and improved range of motion. Muscle strains heal noticeably faster. Inflammation at chronic injury sites decreases. Week 4–8: Significant healing progress. Many acute soft tissue injuries show substantial or complete resolution. Chronic injuries continue improving. Hair growth in areas of thinning may become apparent. Skin quality improves — cuts and wounds heal faster. Week 8–12: Full effects are evident. Many chronic injuries show significant improvement or resolution. Joint mobility and flexibility are enhanced. Recovery from training is markedly improved. Transition to maintenance dosing. Post-cycle: Some benefits persist for weeks to months after discontinuation, as structural tissue repairs are maintained. However, the anti-inflammatory and recovery-enhancing effects diminish.

Common Stacks

Storage & Handling

Store lyophilized TB-500 at 2–8°C for up to 18 months. For long-term storage, -20°C extends stability to 2+ years. Reconstitute with bacteriostatic water — add water slowly down the vial wall and swirl gently. Do not shake. Reconstituted TB-500 should be stored at 2–8°C and used within 21–28 days. Protect from light. The peptide is relatively stable but degrades with heat exposure. Do not freeze reconstituted solution.

Pricing & Available Variants

$65price range
10mg

Prices sourced from peptides.gg marketplace. Prices may vary.

References

  1. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026.
  2. Tham A, Hodgkins CW, Kennedy JG. Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500. J Am Acad Orthop Surg. 2026.
  3. Esposito S, Deventer K, Goeman J, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012.
  4. Sosne G, Qiu P, Goldstein AL, et al. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J. 2010.
  5. Philp D, Huff T, Gho YS, et al. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J. 2003.
  6. Philp D, Badamchian M, Scheremeta B, et al. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2003.
  7. Rahaman KA, Muresan AR, Min H, et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. J Chromatogr B Analyt Technol Biomed Life Sci. 2024.
  8. Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999.
  9. Sosne G, Szliter EA, Barrett R, et al. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp Eye Res. 2002.
  10. Bock-Marquette I, Saxena A, White MD, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004.
  11. Smart N, Risebro CA, Melville AA, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007.
  12. Philp D, Nguyen M, Scheremeta B, et al. Thymosin beta4 increases hair growth by activation of hair follicle stem cells. FASEB J. 2004.
  13. Sosne G, Qiu P, Christopherson PL, et al. Thymosin beta 4 suppression of corneal NFkappaB: a potential anti-inflammatory pathway. Exp Eye Res. 2007.
  14. Crockford D, Turjman N, Allan C, et al. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci. 2010.
  15. Goldstein AL, Hannappel E, Sosne G, et al. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012.
  16. Ruff D, Crockford D, Girardi G, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010.
  17. Guarnera G, DeRosa A, Camerini R. The effect of thymosin treatment of venous ulcers. Ann N Y Acad Sci. 2010.
  18. Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015.
  19. Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012.
  20. The Prohibited List. World Anti-Doping Agency. 2026.
  21. Morita T, Hayashi K. Tumor Progression Is Mediated by Thymosin-β4 through a TGFβ/MRTF Signaling Axis. Mol Cancer Res. 2018.
  22. Caers J, Hose D, Kuipers I, et al. Thymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma. Haematologica. 2010.
  23. Philp D, Scheremeta B, Sibliss K, et al. Thymosin beta4 promotes matrix metalloproteinase expression during wound repair. J Cell Physiol. 2006.
  24. Sosne G, Xu L, Prach L, et al. Thymosin beta 4 stimulates laminin-5 production independent of TGF-beta. Exp Cell Res. 2004.
  25. Jo JO, Kim SR, Bae MK, et al. Thymosin β4 induces the expression of vascular endothelial growth factor (VEGF) in a hypoxia-inducible factor (HIF)-1α-dependent manner. Biochim Biophys Acta. 2010.
  26. Zhang Y, Dong Q, Bian X, et al. Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion. Cardiovasc Res. 2025.
Deep dive

TB-500 vs BPC-157

Read the full guide

Related Peptides

Track TB-500 (Thymosin Beta-4) in Your Protocol

Log your TB-500 (Thymosin Beta-4) doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.

Start Tracking Free